Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Comparative Safety and Efficacy Study of ACTHar Gel Alone or in Combination With Oral Tacrolimus to Reduce Urinary Proteinuria in Patients With Idiopathic DNAJB9 Positive Fibrillary Glomerulopathy

NCT05546047 is registered in ClinicalTrials.gov with NephroNet, Inc. as lead sponsor.

NCT NCT05546047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05546047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Comparative Safety and Efficacy Study of ACTHar Gel Alone or in Combination With Oral Tacrolimus to Reduce Urinary Proteinuria in Patients With Idiopathic DNAJB9 Positive Fibrillary Glomerulopathy
Lead sponsor
NephroNet, Inc.
Phase
Phase 4
Overall status
Unknown status
Start date
March 14, 2019
Completion date
October 27, 2024
Enrollment
34 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fibrillary glomerulonephritis